Unlawful Stem Cell Products Continue to Harm People as FDA Deadline Looms

Congressional oversight could boost efforts to ensure safe, effective regenerative therapies

Unlawful Stem Cell Products Continue to Harm People as FDA Deadline Looms

More than two years after the Food and Drug Administration updated its regulatory framework for regenerative medicine, hundreds of businesses continue to sell unapproved stem cell products and other drugs derived from human blood and tissue.

The framework clarified how the agency would oversee the growing market for these products, and it encouraged the development of new therapies while also aiming to restrain the proliferation of unproven—and often dangerous—stem cell treatments.

Businesses were given three years to come into compliance, a period that ends this November. But the FDA has signaled that many clinics and providers have yet to heed approval requirements for their products.

Read the remainder of this article at The Hill.

America’s Overdose Crisis
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Quick View

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?